摘要
目的:探讨桂枝芍药知母汤联合甲氨蝶呤(MTX)和柳氮磺吡啶(SSZ)治疗难治性类风湿关节炎(RA)的疗效和安全性。方法:选择符合纳入标准患者81例,随机分为治疗组和对照组,治疗组40例给予桂枝芍药知母汤、MTX和SSZ治疗,对照组41例给予MTX和SSZ治疗,疗程均为12周。采用美国风湿病学会(ACR)推荐的RA疾病活动评价核心指标对两组治疗前后进行评估。结果:治疗后2组病情活动主要指标评分均有显著降低,治疗前后比较,差异均有非常显著性意义(P<0.01),治疗组评分降低优于对照组,差异有显著性意义(P<0.05)。治疗组达到ACR20,ACR50,ACR90疗效标准的分别为:37.5%,32.5%,20%,总有效率90%;对照组达到ACR20,ACR50,ACR90疗效标准的分别为:46.34%,19.51%,4.88%,总有效率70.73%。结论:桂枝芍药知母汤联合MTX和SSZ治疗难治性RA疗效明显优于MTX联合SSZ的疗效,且具有较好的安全性。
Objective：Explore the efficacy and safety of Guizhi Shaoyao Zhimutang combine methotrexate （MTX） and sulfasalazine （ SSZ） on refractory rheumatoid arthritis （ RA）.Method：Select 81 patients met the inclusion criteria were randomly divided into two groups.Patients in treatment group （ n=40） were treated with Guizhi Shaoyao Zhimutang combine methotrexate （MTX） and sulfasalazine （SSZ）.Patients in control group （n=41） were treated with methotrexate （MTX） and sulfasalazine （SSZ）.The therapeutic course was 12 weeks in both groups.Based on American college of rheumatology （ ACR） recommended evaluation of RA disease activity core set of indicators to assess the two groups before and after treatment.Result：After treatment,both groups score major indicators of disease activity were significantly decreased ,before and after treatment the differences were highly statistically significant （P〈0.01）,the treatment group score lower than the control group,the difference was significant （P〈0.05 ）.The treatment group achieved ACR20,ACR50,ACR90 efficacy criteria were：37.5% , 32.5% ,20% ,with a total effective rate 90% ; the control group achieved ACR20,ACR50,ACR90 efficacy criteria were：46.34% ,19.51% ,4.88 % ,the total efficiency of 70.73% .Conclusion：Guizhi Shaoyao Zhimutang combine methotrexate （MTX） and sulfasalazine （SSZ） the efficacy of the treatment of refractory rheumatoid arthritis is superior to the efficacy of methotrexate （MTX） and sulfasalazine （SSZ）,and has good security.
出处
《中国实验方剂学杂志》
CAS
北大核心
2010年第8期201-203,共3页
Chinese Journal of Experimental Traditional Medical Formulae
